Effects of  polysaccharides on airway inflammation of lungs in an asthma mouse model by unknown
Lin et al. Multidisciplinary Respiratory Medicine  (2015) 10:20 
DOI 10.1186/s40248-015-0017-0ORIGINAL RESEARCH ARTICLE Open AccessEffects of Laminaria japonica
polysaccharides on airway inflammation of
lungs in an asthma mouse model
Rongjun Lin1*, Xiaomei Liu1, Yan Meng2, Mei Xu3 and Jianping Guo4Abstract
Background: Asthma is a serious chronic inflammatory disease affecting 300 million people worldwide. This aim of
this study to investigate the anti-inflammatory and anti-asthmatic effects of Laminaria japonica extract in the
ovalbumin (OVA)-induced mouse asthma model.
Methods: A mouse asthma model was established in SPF Kunming mice by OVA-sensitization followed by inhalation
of aerosol allergen for two weeks. Laminaria japonica polysaccharides (LJPS) were given by gavage feeding at 50 mg/
kg/day during OVA inhalation challenge period, and their effect on asthma was compared with the standard
treatment of Budesonide inhalation. The total inflammatory cells and eosinophils in bronchoalveolar lavage fluid
(BALF) were determined. Histopathological changes in lung tissue were studied and scored to determine the
degree of inflammation. Levels of IL-12, IL-13, and TGF-β1 in BALF as well as serum levels of IgE were measured.
Expressions of IL-12, IL-13, and TGF-β1 in lung tissues were assessed.
Results: Highly inflammatory lungs infiltrated with significant increased eosinophils were observed in OVA-
induced asthmatic mice. The OVA treated mice presented with a lower level of IL-12 and higher levels of IL-13
and TGF-β1 in BALF and lung tissues, as well as an increased level of the serum IgE. Treatment with LJPS (Group
B) significantly decreased the numbers of eosinophils in the BALF (P < 0.05) and alleviated lung inflammation
compared to the untreated asthma mice (Group A). It also reduced the serum IgE levels, increased expression of
IL-12, and decreased the expression of IL-13 and TGF-β1 in BALF and lung (Both P < 0.05) compared with the
group A.
Conclusions: LJPS can significantly inhibit airway inflammation of asthmatic mice, adjust the balance of
cytokines, and improve the pulmonary histopathological condition. Our data suggested that LJPS might be a
potential therapeutic reagent for allergic asthma.
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Asthma is a serious chronic inflammatory disease char-
acterized by reversible lung airway obstruction [1]. The
incidence of asthma has been on the rise globally. It is
estimated that asthma affects 300 million people and
contributes to 250,000 annual deaths worldwide. Patho-
logically, patients are found to have bronchial mucosal* Correspondence: linrongjun0312@126.com
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overproduction, and eosinophil infiltration [2].
The general approach of current asthma therapy is to
control the inflammatory response in the airways using cor-
ticosteroids. The commonly used treatments for asthma in-
clude bronchodilators of long-acting beta agonists and
muscarinic antagonists or anti-inflammatory drugs such as
corticosteroids. While corticosteroids are very effective in
controlling the symptoms, there are 5–10 % of asthma pa-
tients who are glucocorticoid insensitive. The side effects of
corticosteroids have been the major concern, and the thera-
peutic effects are far from fully satisfactory [3, 4]. Despitee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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the field of asthma research, new approaches for asthma
treatment are necessary to ensure alleviation of symptoms
in all patients.
Traditional Chinese medicines are gaining recognition
for their therapeutic effect in alleviating asthmatic symp-
toms. Laminaria japonica polysaccharides (LJPS), an ex-
tracted mixture containing alginic acids, laminarans and
sulfated polysaccharides (fucoidans) from the brown sea
algae Laminaria japonica, have been investigated in vari-
ous studies for its biological function. These polysaccha-
rides have been implicated in a number of functions,
including antioxidant and free radicals scavenging, anti-
inflammatory, antitumor, reducing blood lipids, and
anti-diabetes [5–7]. In this study, we further analyzed
the anti-inflammatory properties of LJPS in a mouse
model of allergic asthma that mimicked asthma in pa-
tients. Our data suggested that LJPS suppressed inflam-
mation and had a therapeutic potential for asthma.
Material and methods
Mice
Female SPF Kunming mice aged 6–8 weeks (18–22 g)
were purchased from the Experimental Animal Center.
The protocols of animal experiments were reviewed and
approved by the Institute of Animal Care and Use Com-
mittee of the Qingdao Medical University. The animals
were maintained in the clean barrier animal facilities
under specific pathogen-free conditions. All animals
were euthanized by CO2 chamber.
Ovalbumin (OVA)-induced asthma mouse model and
treatment procedures
An OVA-induced asthma mouse model was established
as described in previous studies with modifications [8].
Started from 21 days after initial administration of OVA
(Sigma-Aldrich, USA), mice were randomly grouped and
treated differently for two weeks as the following groups:
A, untreated group; B, LJPS-treated groups; and C,
Budesonide-treated group. Control animal (group D)
was sensitized and challenged with PBS without OVA.
Each group was set with 10 mice. No treatment was ap-
plied to control mice. LJPS was given at 50 mg/kg in
normal saline (Jinan, China) per day through gavage
feeding. Budesonide (AstraZeneca, UK) was given at
200 pg in 4 ml saline by inhalation daily. Mice were
challenged 30 min daily for two weeks by an inhalation
of 2 % OVA through an air aerification inhaler in an
atomization inhalation chamber.
Preparation of LJPS
Laminaria japonica was harvested in Rongcheng,
Shandong, China. The Laminaria japonica was dried
and pulverized to powder. Dry powder (50 g) was mixedwith 1000 ml of distilled water with 0.02 % (w/w) cellu-
lose enzyme, 0.05 % (w/w) papain, and 0.05 % (w/w)
neutral protein enzyme, and then incubated at 70 °C for
6 h followed by another 12 h incubation at room
temperature after adjusting pH to 10.0. The mixture was
centrifuged at 500 g for 15 min and supernatant (A) was
collected. 500 ml of 10 % HCl was added to the pellet,
incubated at room temperature for another 4 h, and cen-
trifuged again (500 g, 15 min) and supernatant (B) was
collected. The supernatant (B) was combined superna-
tants (A) and precipitated with 80 % ethanol. The pre-
cipitate was subjected to DEAE cellulose column
chromatography. The final product was measured as
glucose (5.6 %), mannose (22.10 %), rhamnose (7.0 %),
galactose (8.0 %), and xylose (56.2 %). The molecular
weight of polysaccharide was 67 kDa.
BALF collection and cell count
24 h after the last OVA challenge, the animal was anes-
thetized with an i.p. injection of 10 % chloral hydrate
(Sigma-Aldrich, USA) in PBS, and then the trachea was
cannulated. Bronchoalveolar lavage was performed by
flushing 0.3 ml of PBS into the trachea through the can-
nula, and the cells in the lung were collected in bron-
choalveolar lavage fluid (BALF). The process was
repeated three times.
The BALF was immediately centrifuged at 3000 RPM/
min for 5 min at 4 °C. The supernatant was stored at−20 °
C. Pellets were re-suspended in 50 μl PBS. Total cell
counts were determined, and differential cell counts were
determined according to standard morphological criteria.
The number of eosinophils in every 200 inflammatory
cells in BALF was calculated.
Histological examination of lung tissues
Histological examination was performed by Hematoxylin
and Eosin (HE) staining as described previously with minor
modifications [8]. Briefly, animal was euthanized 24 h after
the last OVA challenge or PBS inhalation., The middle lobe
of the right lung was excised, fixed in 4 % formalin, and
embedded in paraffin after the left lung had been lavaged.
Sections of 5 μm were de-paraffinized and hydrated, and
then stained with HE or immunohistochemistry staining.
Histopathological assessment (light microscopy) on
randomly selected sections was performed by a patholo-
gist who was blinded from the experiment. Inflammatory
responses were graded using a semi-quantitative scale of
0–5 for epithelial damage, perivascular eosinophilia,
peribroncholar eosinophilia, and edema as described
previously [2].
ELISA
Quantitative assessments of IL-12, IL-13 and TGF-β1
in BALF were conducted using enzyme linked
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USA.), whereas serum IgE levels were assessed using
ELISA kit (Beijing Zhongshan Golden Bridge, China)
according to the manufacturers’ instructions.
Immunohistochemistry for IL-12, IL-13 and TGF-β1
Sections of lung tissue were studied by immunohisto-
chemistry methods to detect and localize IL-12, IL-13
and TGF-β1 protein expression using corresponding
rabbit polyclonal antibodies (Beijing Golden Bridge Co.,
China). Chromogen 3,3-diaminobenzidine (Beijing
Golden Bridge Co., China) was used as substrate, and
sections counterstained with PBS instead of primary
antibody were used as negative control.
Statistical analysis
Statistical analysis was performed with the SPSS 17.0
software (IBM, USA). Data were expressed as mean ±
SEM (standard error of the mean). Differences between
the means of two groups were determined by one-way
ANOVA. Paired t-tests were used to assess the statistical
differences between the paired samples. In all cases, if a
p value was less than 0.05, it would be considered statis-
tically significant.
Results
Manifestation of allergen-induced asthmatic mice
Mice challenged with OVA inhalation showed obvious
signs of sickness, including sneezes, nose rubbing,
breathing deeply and fast, lip and eye cyanosis, ruffled
fur, forelimb shrinkage lift, stooping, irritability, and
other various degrees of asthma immediate responses.
These symptoms persisted in mice treated with PBS
(Group A); however, in mice treated with either LJPSFig. 1 a–d. Histopathological changes of the experimental mice with vario
treated with PBS (a), LJPS (b), Budesonide (c), and PBS treated control mice(Group B) or Budesonide (Group C) alleviated symp-
toms were observed. The mice in the control group
(Group D) did not show any of the above symptoms.Anti-inflammatory effects of LJPS in allergic asthma
Significant eosinophil infiltration was observed by HE
staining of sections from OVA-challenged mice in both
perivascular and peribronchial areas (Fig. 1a). The in-
flammation was greatly alleviated when treated with ei-
ther LJPS or Budesonide (Fig. 1, b and c, Group B and
C), whereas no eosinophil infiltration was found in the
control group (Fig. 1d, Group D). The pathological score
of lung tissue was graded according to the degree of
perivascular eosinophilia, peribroncholar eosinophilia,
epithelial damage, and edema with a semi-quantitative
scale (Table 1). The pathological scores were signifi-
cantly higher for in OVA challenged mice than the con-
trol mice (P < 0.05 by paired t test). Treatment with
either LJPS (Group B) or Budesonide (Group C) was
able to bring down the pathological scores of the lung
tissues in these asthmatic mice (P < 0.05 in comparison
of OVA challenged group by paired t test).
The inflammatory cell and eosinophil count in BALF
further demonstrated that LJPS treatment could reduce
the OVA-induced hyper-responsiveness similar to what
was observed with Budesonide treatment. BALF was col-
lected 24 h after the last OVA or PBS aerosol inhalation.
As shown in Table 2, the total inflammatory cell number
in BALF from OVA challenged mice was significantly el-
evated compared to that from mice of PBS inhalation.
Both Budesonide (Group C) and LJPS (Group B) treat-
ment significantly reduced the inflammatory cell count
in BALF for the asthmatic mice (P < 0.05 by ANOVA test).us treatments. Lung sections of the OVA-induced asthmatic mice
(d) were stained with Hematoxylin and eosin
Table 1 Histopathological analysis of lung tissue sections
Group # Eosinophil infiltration Edema Airway epithelial
A 10 4 (1–5) 4 (2–5) 4 (2–5)
B 10 2 (1–4) 3 (1–3) 1 (0–2)
C 10 1 (0–1) 1 (0–1) 0 (0–0)
D 10 1 (0–1) 0 (0–0) 0 (0–0)
Group A, B, C were challenged with OVA. A, treated with PBS; B, treated with
LJPS; C, treated with Budesonide; D, control group challenged by PBS. Data
were expressed as median (range)
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As shown in Fig. 2a, OVA-challenged mice had a signifi-
cantly higher serum IgE level of 31.65 ng/ml, while the IgE
level from control mice was 16.19 ng/ml (P < 0.05 by
ANOVA test). LJPS treatment (Group B) was able to re-
duce the IgE level to 26.07 ng/ml, (P < 0.05 comparing
to OVA challenged mice by ANOVA test), which was
similar to the effect of Budesonide treatment (24.25 ng/
ml, Group C).
Cytokine in BALF and expression in lung tissue
We investigated whether LJPS can reduce inflammation
by similar down-regulation of the Th2 cytokines. Cyto-
kine in the BALF was measured by ELISA. As shown in
Fig. 2, b-d, the level of IL-12 was greatly reduced in
OVA-challenged mice compared to the control, while
IL-13 and TGF-β1 were greatly increased. All these
changes were reversed with the treatment of LJPS or
Budesonide. We observed significantly increased IL-12
level as well as reduced levels of IL-13 and TGF-β1 in
BALF from LJPS or Budesonide treated mice (P < 0.05).
We further studied the localization of these cytokines
in situ in the formalin-fixed, paraffin-embedded lung tis-
sue sections. IL-12 expression was reduced in the lungs
of asthmatic mice compared to those of the un-induced
control; expression was mostly localized in the cyto-
plasm of the bronchial epithelial cells (Fig. 3a and d).
We observed higher expression of IL-12 in both LJPS
and Budesonide-treated asthmatic mice than in the non-
treated asthmatic mice (Fig. 3b and c vs. a). On the other
hand, the levels of IL-13 were significantly elevated in
the lung tissues of OVA-induced asthmatic mice (Fig. 4a)Table 2 Infiltrated inflammatory cell count in BALF (×105/ml)
Groups # WBC Eosinophils
A 10 23.09 ± 3.09 3.42 ± .42
B 10 11.51 ± 1.51* 0.38 ± .381*
C 10 9.13 ± .131 0.09 ± 0.07
D 10 6.84 ± .841 0.07 ± .071
Group A, B, C were challenged with OVA followed by treatment with PBS (A),
LJPS (B), or Budesonide (C) respectively. Group D was the control group
challenged by PBS. Data were expressed as mean ± SEM. P < 0.05 in groups B,
C, and D vs group A
*,P < 0.05 in group B vs group Ccompared to the PBS control mice (Fig. 4d). LJPS treat-
ment led to the down-regulation of IL-13 expression,
similar to the treatment of Budesonide (Fig. 4b and c).
IL-13 was also seen mostly in the cytoplasm of bronchial
epithelial cells.
TGF-β1 expression was markedly increased in the lung
tissues of OVA-induced asthmatic mice (Fig. 5a), re-
duced in both LJPS and Budesonide treated mice (Fig. 5b
and c), while little or no expression was detected in the
lung tissue of PBS-sensitized normal mice (Fig. 5d).
Strong cytoplasmic staining was observed in bronchial
epithelial cells, connective tissue of the lamina propria
and adventitia, smooth muscle cells, and inflammatory
cells (Fig. 5a).
Discussion
Inflammatory responses were assessed in situ by histo-
logic evaluation of lung tissue sections as well as cell
counts in the retrieved BALF. The effect of LJPS on lung
inflammation in the asthmatic mice was compared to
that of Budesonide, one of the most effective anti-
inflammatory drugs used in allergic asthma treatment.
OVA-induced asthmatic model is a well-established
animal model for studying the mechanism of asthma
and therapeutic effects of drugs. Upon OVA challenge,
the mice exhibited similar symptoms to those found in
patients with chronic asthma, including different degrees
of immediate asthma reactions, eosinophil infiltration
into the lung interstitium and BALF, as well as epithelial
damage in the lung. Therefore, it provided an ideal
model to mimic clinical reality.
Polysaccharides are considered as T-cell independent
antigens that only elicit humoral immune response in
general. However, recent studies pointed out that certain
polysaccharides could be strong immune modulators.
Several clinical studies have revealed its effect on in-
creasing the number of cytotoxic T cells and the phago-
cytic capacity of monocytes, as well as reducing
inflammatory cytokines [9, 10]. We employed LJPS in
the treatment of experimental asthma and found that it
reduced airway inflammation in the mouse asthma
model. We found that oral treatment of LJPS in OVA-
induced asthmatic mice exhibited symptom alleviation
similar to treatment with Budesonide. The inflammation
in the lung tissue was reduced, as were the infiltrating
inflammatory cells, including eosinophils.
It has been known that the imbalance of Th1 and Th2
cytokines is responsible for the pathogenesis of asthma.
Th2 cytokines were found to be up-regulated in asthma
that led to over production of TGF-β1, while Th1 cyto-
kine expression was suppressed. Infiltration of mono-
nuclear cells, mostly CD4 T helper type 2 cells (Th2)
and eosinophils, in the airway wall underlines the major
pathogenesis of asthma. A dominant Th2 response
Fig. 2 a–d. Immune responses of OVA-challenged mice upon various treatments. Serum IgE levels (a), and cytokine levels of IL-12 (b) (c) IL-13
TGF-β1 (d) in BALF of the OVA-induced asthmatic mice underwent various treatments were assessed and statistical analysis was performed
Fig. 3 a–d. Expression and localization of IL-12 in the lung tissue. IL-12 protein was detected by Immunohistochemistry in tissue sections from OVA-
induced asthmatic mice treated with PBS (a), LJPS (b), and Budesonide (c), as well as PBS-treated control mice (d). The cytoplasm and nucleus in
positive cells appeared brown yellow fine particles in lung tissues
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Fig. 4 a–d. Expression and localization of IL-13 in the lung tissue. IL-13 protein was detected by Immunohistochemistry in tissue sections from OVA-
induced asthmatic mice treated with PBS (a), LJPS (b), and Budesonide (c), as well as PBS-treated control mice (d). The cytoplasm and nucleus in
positive cells appeared brown yellow fine particles in lung tissues
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an elevated level of IgE, eosinophil recruitment, and
mast cell activation, has been directly linked to asthma
severity. Th2-type cytokines IL-4, IL-5, and IL-13 have
been implicated in promoting allergic responses in
asthma [11, 12]. These cytokines, IL-13 in particular,
play critical roles in the human allergic responses. IL-13
has been shown to potentiate IgE production, upregulate
the expression of adhesion molecules, as well as induceFig. 5 a–d. Expression and localization of TGF-β1 in the lung tissue. TGF-β1
from OVA-induced asthmatic mice treated with PBS (a), LJPS (b), and Bude
nucleus in positive cells appeared brown yellow fine particles in lung tissuemucus hyper-secretion and airway hyper-responsive
[13, 14]. Th1-type cytokine IL-12, on the other hand, is
involved in reducing allergen-specific IgE and airway
eosinophilia [15, 16]. Asthmatic patients had significantly
reduced levels of IL-12 in both peripheral blood and air-
way biopsy specimens compared with their healthy coun-
terparts [17]. IL-12 is known to promote T cell
differentiation toward a Th1-mediated response while sup-
pressing the expansion and differentiation of Th2 cellsprotein was detected by Immunohistochemistry in tissue sections
sonide (c), as well as PBS-treated control mice (d). The cytoplasm and
s
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type cytokines, and reduces eosinophilic inflammation.
LJPS treatment, similarly to Budesonide, reduced the
levels of IL-13 in both BALF and lung tissue in situ in the
asthmatic mice, and restored IL-12 expression in lung,
therefore to re-establish the balance of Th1 and Th2 im-
munity. As a consequence, the serum IgE levels were also
reduced after LJPS treatment.
Structural changes, namely airway remodeling, occur in
the airways of asthmatic patients. These changes include
goblet cell hyperplasia, increased thickness of subepithelial
basement membrane, increased mass and size of airway
smooth muscle (ASM), and fibrosis. TGF-β, a potent profi-
brotic cytokine, is a major player in regulating airway re-
modeling [19, 20]. TGF-β induces the expression and
release of profibrotic and proinflammatory cytokines in fi-
broblasts and ASM cells. It can also serve as a chemo-
attractant for monocytes, fibroblasts, and mast cells. The
level of TGF-β was found to increase in both mild and se-
vere asthmatics, and its level correlates with basement
membrane thickness [21, 22]. Eosinophils, macrophages,
and fibroblasts were reported as the main sources of TGF-
β1 [22–24]. Scherf et al. showed that TGF-β1 could in-
crease levels of the Th2 cytokines, including IL-4, IL-5, and
IL-13, resulting in an increased inflammatory response in
the lung [25]. We found in our study that TGF-β1 levels in-
creased in both the BALF and lung tissue sections of the
OVA-induced asthmatic mice. LJPS treatment led to an al-
most 40 % reduction of TGF-β1 levels in these mice, similar
to the reduction caused by Budesonide treatment. The re-
duction of TGF-β1 level clearly correlates to the histopath-
ology seen in these mice, and to the reduction of eosinophil
infiltrations seen after treatment. Previously, Xiong et al.
[26] reported that a Chinese herbal medicine, (±)-Praerup-
torin A, was able to reduce the expression of TGF-β1 in an
OVA-sensitized asthma model. In their study, the reduction
of TGF-β1 was also concurrent with the improvement of
lung inflammation. We hypothesize that LJPS may inhibit
mouse airway inflammation through reduction of the ex-
pression of TGF-β1.
Polysaccharides are usually recognized by TLR4 in in-
ducing native immune response. Study has shown that
sulfated polysaccharides from sea brown algae can inter-
act with TLR2 and TLR4 in vitro using transfected HEK
cells [27]. It has also been shown that fucose-containing
sulfated polysaccharides, may induce dendritic cell mat-
uration, promoting IL-12, TNFα production [28, 29].
Another study showed that the dietary fucoidan acti-
vated the T-cell mediated cytotoxic activity and NK cell
function [30]. It is possible that LJPS modulates the in-
flammation in the asthmatic response through cytokines
produced by activated native immunity. Future studies
on the effect of LJPS on macrophages and NK cell activ-
ities will provide clues to its mechanisms.The study was limited by the use of the OVA-induced
asthma mouse model, which defined the application po-
tential of the LJPS in allergic asthma. For non-allergic
asthma, the therapeutic efficacy of LJPS needs to be fur-
ther studied.
Conclusion
LJPS could be used as an allergic asthma treatment in a
mouse model. The administration of LJPS alleviated
asthma symptoms, reduced airway inflammation by re-
ducing Th2 cytokines and increasing a Th1 cytokine, as
well as reducing the expression of TGF-β1 in lung.
These results suggested that LJPS has a significant anti-
inflammatory effect on allergen-induced lung inflam-
mation in this asthma mouse model, providing a strat-
egy for adoptive immunotherapy for asthma treatment
without immune suppression.
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